Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment

Molecular Genetics and Metabolism

Volumn 116, Issue 1-2, 2015, Pages 61-68

  Shapiro, Elsa G ^a   Nestrasil, Igor ^a   Rudser, Kyle ^a   Delaney, Kathleen ^a   Kovac, Victor ^a   Ahmed, Alia ^a   Yund, Brianna ^a   Orchard, Paul J ^a   Eisengart, Julie ^a   Niklason, Gregory R ^a   Raiman, Julian ^b   Mamak, Eva ^b   Cowan, Morton J ^c   Bailey Olson, Mara ^c   Harmatz, Paul ^c   Shankar, Suma P ^d   Cagle, Stephanie ^d   Ali, Nadia ^d   Steiner, Robert D ^e,f   Wozniak, Jeffrey ^a   Lim, Kelvin O ^a   Whitley, Chester B ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f MARSHFIELD CLINIC   (United States)

Author keywords

Genotypes; Mucopolysaccharidosis Type I; Neurocognition; Neuroimaging

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BRAIN SIZE; CHILD; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME REPLACEMENT; FEMALE; GENOTYPE; GRAY MATTER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; INFANT; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; WHITE MATTER; ANATOMY AND HISTOLOGY; CLINICAL TRIAL; COGNITION DISORDERS; MUCOPOLYSACCHARIDOSIS I; OUTCOME ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COGNITION; COGNITION DISORDERS; ENZYME REPLACEMENT THERAPY; FEMALE; GRAY MATTER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MUCOPOLYSACCHARIDOSIS I; PATIENT OUTCOME ASSESSMENT; WHITE MATTER; YOUNG ADULT;

EID: 84940893067     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.06.002     Document Type: Article

References (48)

1. Muenzer J., Wraith J.E., Clarke L.A. Mucopolysaccharidosis I: management and treatment. Pediatrics 2009, 123:19-29. The International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis I.
2. Boelens J., Prasad V., Tolar J., Wynn R., Peters C. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr. Clin. N. Am. 2010, 57:123-145.
3. Vijay S., Wraith J.E. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005, 94:872-877.
4. Ahmed A., Whitley C.B., Cooksley R., et al. Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the alpha-l-iduronidase gene in Hurler-Scheie syndrome. Mol. Genet. Metab. 2014, 111:123-127.
5. Al Sawaf S., Mayatepek E., Hoffmann B. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J. Inherit. Metab. Dis. 2008, 31(4):473-480.
6. Shapiro E., Balthazor M. Metabolic and neurodegenerative disorders of childhood. Pediatric Neuropsychology: Research, Theory and Practice 1999, 171-205. Guilford Press, New York, NY. G. Taylor, D. Ris, K. Yeates (Eds.).
7. Shapiro E.G., Lockman L.A., Balthazor M., Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 1995, 18:413-429.
8. Delaney K., Rudser K., Yund B., Whitley C., Haslett P., Shapiro E. Methods in neuropsychological assessment in children with neurodegenerative disease: Sanfilippo syndrome. J. Inherit. Metab. Dis. Rep. 2013, 10.1007/8904_2013_269.
9. Giedd J.N., Rapoport J.L. Structural MRI of pediatric brain development: what have we learned and where are we going?. Neuron 2010, 67(5):728-734.
10. Casey B.J., Giedd J.N., Thomas K.M. Structural and functional brain development and its relation to cognitive development. Biol. Psychol. 2000, 54(1):241-257.
11. Mullen E.M. Mullen Scales of Early Learning 1995, American Guidance Service, Circle Pines MN.
12. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence 2002, Psychological Corporation, San Antonio TX. 3rd ed.
13. Wechsler D. Wechsler Abbreviated Scale of Intelligence 1999, Psychological Corporation, San Antonio TX.
14. Bayley N. Bayley Scales of Infant Development 1969, Psychological Corporation, San Antonio TX.
15. Thorndike R.L., Hagen E.P., Sattler J.M. Stanford-Binet Intelligence Scale 1986, Riverside, Chicago. Fourth ed.
16. Ahmed A., Kunin-Batson A., Redtree E., Whitley C.B., Shapiro E. MPS (mucopolysaccharidosis) specific physical symptom score-development, reliability and validity. Mol. Genet. Metab. 2014, 111(2):S17-S18.
17. Fischl B. FreeSurfer. Neuroimage 2012, 62(2):774-781.
18. R Core Team R: A language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, Austria, (URL http://www.R-project.org/).
19. Aldenhoven M., Boelens J., de Koning T.J. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol. Blood Marrow Transplant. 2008, 14:485-498.
20. Souillet G., Guffon N., Maire I., et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003, 31:1105-1117.
21. Peters C., Balthazor M., Shapiro E., et al. Outcome of unrelated donor bone marrow transplantation in forty children with Hurler syndrome. Blood 1996, 87:4894-4902.
22. Peters C., Shapiro E., Anderson J., et al. Hurler Syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998, 91:2601-2608.
23. Martin H.R., Poe M.D., Reinhartsen D., et al. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Pediatr. 2008, 97:69-75.
24. Lücke T., Das A.M., Hartmann H., et al. Developmental outcome in five children with Hurler syndrome after stem cell transplantation: a pilot study. Dev. Med. Child Neurol. 2007, 49(9):693-696.
25. Malm G., Gustafsson B., Berglund G., et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr. 2008, 97(8):1108-1112.
26. Eisengart J.B., Rudser K.D., Tolar J., et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J. Pediatr. 2013, 162(2):375-380.
27. Wynn R., Mercer J., Page J. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J. Pediatr. 2009, 154:135-139.
28. Tolar J., Grewal S., Bjoraker K., et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2007, 41:531-535.
29. Terlato N.J., Cox G.F. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet. Med. 2003, 5(4):286-294.
30. Poe M.D., Chagnon S.L., Escolar M.L. Early treatment is associated with improved cognition in Hurler syndrome. Ann. Neurol. 2014, 76(5):747-753.
31. Krivit W., Lockman L.A., Watkins P.A., Hirsch J., Shapiro E.G. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J. Inherit. Metab. Dis. 1995, 18(4):398-412.
32. Weisstein J.S., Delgado E., Steinbach L.S., et al. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J. Pediatr. Orthop. 2004, 24:97-101.
33. Hite S.H., Peters C., Krivit W. Correction of odontoid dysplasia following bone-marrow transplantation and engraftment (in Hurler syndrome MPS 1H). Pediatr. Radiol. 2000, 30:464-470.
34. Thomas J.A., Beck M., Clarke J.T., Cox G.F. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J. Inherit. Metab. Dis. 2010, 33(4):421-427.
35. Shapiro E., Guler O.E., Rudser K. An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT). Mol. Genet. Metab. 2012, 107(1):116-121.
36. Vedolin L.I., Schwartz V.D., Komlos M. Brain MRI in mucopolysaccharidosis effect of aging and correlation with biochemical findings. Neurology 2007, 69(9):917-924.
37. Matheus G.M., Castillo J.K., Smith, et al. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 2004, 46:666-672.
38. Vite C., Nestrasil I., Mlikotic A., et al. Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I. Comp. Med. 2013, 63:163-173.
39. Dickson P., McEntee M., Vogler C., et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
40. Ou L., Herzog T., Koniar B.L., Gunther R., Whitley C.B. High-dose enzyme replacement therapy in murine Hurler syndrome. Mol. Genet. Metab. 2014, 111:116-122.
41. Anderson F.S., Kunin-Batson A.S., Perkins J.L., et al. White versus gray matter function as seen on neuropsychological testing following bone marrow transplant for acute leukemia in childhood. Neuropsychiatr. Dis. Treat. 2008, 4(1):283-288.
42. Anderson F.S., Kunin-Batson A.S. Neurocognitive late effects of chemotherapy in children: the past 10years of research on brain structure and function. Pediatr. Blood Cancer 2009, 52:159-164.
43. Reddick W.E., Shan Z.Y., Glass J.O., et al. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 2006, 106:941-949.
44. Zafeiriou D.I., Batzios S.P. Brain and spinal MR imaging findings in mucopolysaccharidoses: a review. Am. J. Neuroradiol. 2013, 34(1):5-13.
45. Walkley S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 2004, 15(4):433-444.
46. Ohmi K., Greenberg D.S., Rajavel K.S., et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. 2003, 100:1902-1907.
47. Pereira V.G., Martins A.M., Micheletti C., D'Almeida V. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin. Chim. Acta 2008, 387:75-79.
48. Campos D., Monaga M. Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms. Metab. Brain Dis. 2012, 27(2):121-129.